Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:37:30.778Z.
Calculation as of: 2026-10-06T19:37:30.778Z.
Quote observation: 2026-10-06T19:34:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85842aa9b6cc8ebfa961f669867d571d507c26eab2d350d24b64fb3509ac0979
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$21.90M
EV/EBIT Ratio
N/A
TTM Avg
21.00x
3Y Avg
21.00x
5Y Avg
21.00x
Market Cap
$24.05M
EV/EBIT Ratio
N/A
TTM Avg
104.01x
3Y Avg
104.01x
5Y Avg
104.01x
Market Cap
$24.42M
EV/EBIT Ratio
N/A
TTM Avg
11456.84x
3Y Avg
11456.84x
5Y Avg
11456.84x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Modular Medical, Inc. (MODD) | $22.17M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.28M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.94M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | N/A | 21.00x | 21.00x | 21.00x |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.15M | N/A | 0.54x | 0.52x | 0.52x |
| Kyntra Bio, Inc. (KYNB)vs › | $24.05M | N/A | 104.01x | 104.01x | 104.01x |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.42M | N/A | 11456.84x | 11456.84x | 11456.84x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $20.25M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.38M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
